Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABT Stock Forecast 2026-2027
$108.14
Current Price
$187.91B
Market Cap
Buy 22
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to ABT Price Targets
+46.1%
To High Target of $158.00
+24.8%
To Median Target of $135.00
+4.5%
To Low Target of $113.00
ABT Price Momentum
-1.3%
1 Week Change
-4.0%
1 Month Change
-16.7%
1 Year Change
-13.7%
Year-to-Date Change
-22.2%
From 52W High of $139.06
+2.7%
From 52W Low of $105.27
📊 TOP ANALYST CALLS
Did ABT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Abbott is one of their latest high-conviction picks.
Latest ABT Stock Price Targets & Analyst Predictions
Based on our analysis of 35 Wall Street analysts, ABT has a bullish consensus with a median price target of $135.00 (ranging from $113.00 to $158.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $108.14, the median forecast implies a 24.8% upside. This outlook is supported by 22 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 46.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABT Analyst Ratings
22
Buy
6
Hold
0
Sell
ABT Price Target Range
Low
$113.00
Average
$135.00
High
$158.00
Current: $108.14
Latest ABT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 2, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $142.00 |
| Jan 23, 2026 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $132.00 |
| Jan 23, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $138.00 |
| Jan 23, 2026 | RBC Capital | Shagun Singh | Outperform | Maintains | $135.00 |
| Jan 23, 2026 | Bernstein | Lee Hambright | Outperform | Maintains | $125.00 |
| Jan 23, 2026 | BTIG | Marie Thibault | Buy | Maintains | $140.00 |
| Jan 23, 2026 | Citigroup | Joanne Wuensch | Buy | Maintains | $140.00 |
| Jan 23, 2026 | Piper Sandler | Adam Maeder | Overweight | Maintains | $135.00 |
| Jan 9, 2026 | Bernstein | Lee Hambright | Outperform | Maintains | $154.00 |
| Jan 5, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $169.00 |
| Nov 20, 2025 | BTIG | Marie Thibault | Buy | Reiterates | $145.00 |
| Oct 17, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $162.00 |
| Oct 16, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $147.00 |
| Oct 16, 2025 | Raymond James | Jayson Bedford | Outperform | Maintains | $146.00 |
| Oct 16, 2025 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $146.00 |
| Oct 16, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $142.00 |
| Oct 15, 2025 | BTIG | Marie Thibault | Buy | Reiterates | $145.00 |
| Oct 10, 2025 | Benchmark | Bruce Jackson | Buy | Initiates | $145.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $144.00 |
| Sep 10, 2025 | Bernstein | Outperform | Maintains | $N/A |
Abbott Laboratories (ABT) Competitors
The following stocks are similar to Abbott based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Abbott Laboratories (ABT) Financial Data
Abbott Laboratories has a market capitalization of $187.91B with a P/E ratio of 29.8x. The company generates $44.33B in trailing twelve-month revenue with a 14.7% profit margin.
Revenue growth is +4.4% quarter-over-quarter, while maintaining an operating margin of +21.6% and return on equity of +13.0%.
Valuation Metrics
Market Cap
$187.91B
Enterprise Value
$197.94B
P/E Ratio
29.8x
PEG Ratio
-0.4x
Price/Sales
4.3x
Growth & Margins
Revenue Growth (YoY)
+4.4%
Gross Margin
+57.0%
Operating Margin
+21.6%
Net Margin
+14.7%
EPS Growth
-80.8%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
1.6x
Debt/Equity
26.8x
ROE
+13.0%
ROA
+6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Abbott Laboratories (ABT) Business Model
About Abbott Laboratories
What They Do
Global healthcare company offering diverse medical products.
Business Model
Abbott Laboratories operates across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company generates revenue through the sale of a wide array of healthcare products, including pharmaceuticals, medical devices, nutritional formulas, and diagnostic equipment, catering to both chronic and acute medical needs.
Additional Information
With a workforce of approximately 114,000 employees and a history dating back to 1888, Abbott Laboratories has a significant international presence, with most of its sales occurring outside the United States. The company is committed to medical innovation and improving patient outcomes, positioning itself as a key player in global health initiatives.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
115,000
CEO
Mr. Robert B. Ford
Country
United States
IPO Year
1983
Website
www.abbott.comAbbott Laboratories (ABT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Abbott (ABT) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mar 11, 2026
By Zacks Equity Research
Tale of the Tape
Abbott (ABT) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mar 10, 2026
By Zacks Equity Research
Tale of the Tape
Abbott (ABT) Rises Higher Than Market: Key Facts
Abbott (ABT) reached $112.65 at the closing of the latest trading day, reflecting a +2.82% change compared to its last close.
Mar 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
The U.K. FreeDM2 trial showed Libre users had a 0.6% greater HbA1c reduction and 2.5 more hours in the healthy range than fingerstick users. An Italian study confirmed similar results.
Why It Matters
The positive results from the FreeDM2 trial highlight the effectiveness of Libre technology in diabetes management, potentially boosting Abbott's market position and driving investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can aid investors in selecting strong stocks that potentially outperform the market for their investment portfolios.
Why It Matters
Zacks Style Scores can help identify high-potential stocks, guiding investors toward selections that may outperform the market and enhance portfolio returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can help identify high-potential stocks, aiding investors in making informed decisions to outperform the market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The stock market may encounter challenges in 2026 due to high valuations, geopolitical tensions, skepticism around AI investments, and adverse policy conditions.
Why It Matters
Rising valuations, geopolitical tensions, skepticism about AI investments, and policy challenges could lead to significant market volatility in 2026, affecting investment strategies and risk assessments.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
Abbott (ABT) closed at $112.65, marking a 2.82% increase from the previous day's closing price.
Why It Matters
Abbott's 2.82% gain indicates positive market sentiment, potentially boosting investor confidence and influencing future stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Abbott Laboratories (ABT) is rated a Buy at $109.56, with strong growth in Devices and Diagnostics. Nutrition poses risks, but a turnaround is expected; the Exact Sciences acquisition may enhance growth.
Why It Matters
Abbott Laboratories' stock is seen as undervalued, with strong growth in key segments, potential for turnaround in Nutrition, and a high-growth acquisition, signaling opportunities for upside.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About ABT Stock
What is Abbott Laboratories's (ABT) stock forecast for 2026?
Based on our analysis of 35 Wall Street analysts, Abbott Laboratories (ABT) has a median price target of $135.00. The highest price target is $158.00 and the lowest is $113.00.
Is ABT stock a good investment in 2026?
According to current analyst ratings, ABT has 22 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $108.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABT stock?
Wall Street analysts predict ABT stock could reach $135.00 in the next 12 months. This represents a 24.8% increase from the current price of $108.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Abbott Laboratories's business model?
Abbott Laboratories operates across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company generates revenue through the sale of a wide array of healthcare products, including pharmaceuticals, medical devices, nutritional formulas, and diagnostic equipment, catering to both chronic and acute medical needs.
What is the highest forecasted price for ABT Abbott Laboratories?
The highest price target for ABT is $158.00 from Matt Miksic at Barclays, which represents a 46.1% increase from the current price of $108.14.
What is the lowest forecasted price for ABT Abbott Laboratories?
The lowest price target for ABT is $113.00 from at , which represents a 4.5% increase from the current price of $108.14.
What is the overall ABT consensus from analysts for Abbott Laboratories?
The overall analyst consensus for ABT is bullish. Out of 35 Wall Street analysts, 22 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $135.00.
How accurate are ABT stock price projections?
Stock price projections, including those for Abbott Laboratories, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 5:42 AM UTC